ELAVL3 stabilizes MYCN mRNA and provides a therapeutic target in neuroendocrine prostate cancer [RIP-seq]
Here we demonstrated that the RNA-binding protein ELAVL3 is specifically upregulated in NEPC, and that overexpression of ELAVL3 alone sufficiently induce neuroendocrine phenotype in prostate adenocarcinoma. We performed RIP-seq of ELAVL3-V5 from 2 prostate cancer cell lines. Overall design: RIP-seq of ELAVL3-V5 from PC3/ELAVL3-V5 and DU145/ELAVL3-V5 cells.